Endoscopic Resection of Bladder Tumors

Endoscopic Resection of High Grade(TA, T1, Cis)Non-muscle Invasive Bladder Tumors: Modification of Usual Management of This Resection by Using the Blue Light and Evaluation of the Outcome: Should we Maintain the Dogma of Second Endoscopic Resection as a Principle?

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01750970

Enrollment

Registered

2012-12-17

Start date

2009-11-30

Completion date

2013-12-31

Last updated

2016-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Tumor

Brief summary

To confirm the benefit of endoscopic resection under fluorescence and blue light of high grade non-muscle invasive bladder tumor, and verifying if the second endoscopic resection recommended nowadays can be deleted.

Interventions

OTHEREndoscopic resection under blue light (Hexvix®)

Endoscopic resection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- 18 year-old and older male and female subjects having high grade non-muscle invasive bladder tumor, with urinary cytology , imaging examination (Ultrasound, urography, or scan) and endoscopic examination

Exclusion criteria

\- Less than 18 years of age, and having no: * Non-muscle invasive tumor, and of low grade. * Bladder tumor infiltrating the muscular layer shown by pre-operative test, with absence of urinary cytology * No blue light source in sustainable way

Design outcomes

Primary

Measure	Time frame
Number of extra lesions revealed by blue light compared to the resection performed in white light	2 to 6 weeks after resection

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026